Autoinflammatory
On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.
Dr. Antoni Chan synovialjoints
3 years 7 months ago
Treatment for VEXAS syndrome. It is steroid responsive. Avoid IL-1 inhibitors severe skin reactions at injection site, bone marrow transplant may be curative @RheumNow #ACR21 Session6S410 L Wilson, DO Cordona https://t.co/eQ1KVDiKKV
Dr. John Cush RheumNow
3 years 7 months ago
JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease
Dr. Bella Mehta ( @bella_mehta) shares abstract findings from #ACR21.
https://t.co/4FyXX5JIyZ https://t.co/YAJOwvLbLS
Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.
Eric Dein ericdeinmd
3 years 7 months ago
#ACR21 L20- Anti-IFN Ab Emapalumab for MAS/sJIA
⭐️⬆️IFN in models of HLH/MAS, neutralization may be helpful
⭐️Pilot study in 14 pts w inadequate response to high-dose IV GC
⭐️Ok to continue IL1i
▶️13/14 pts remission
▶️ SAEs: 1 CMV reactivation
https://t.co/cuM9LcEr4u @RheumNow https://t.co/USYGNtq4eC
Bella Mehta bella_mehta
3 years 7 months ago
Having an auto-inflammatory disease specialist available via telemedicine/video for near home providers for pts. Well received by primary care, pediatricians and internal medicine physicians. Will improve the care of auto inflammatory patients! #ACR21 @rheumnow #abt1062
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 7 months ago
#ACR21 #AbstrL20 A promising new player on the block. A single-arm study of 14 pts with sJIA-associated MAS, Emapalumab (anti-IFNγ) induced remission in all pts with median 25 days, neutralised CXCL9 and allowed rapid steroid reduction @RheumNow #ACRBest https://t.co/7tnaS5tPJ0 https://t.co/G1IoFxLQoX
Dr. John Cush RheumNow
3 years 7 months ago
Emapalumab (IFNg inhibitor) Effective in severe MAS (Ferritin 25K, failed anakinra, GC)- 14 pts (2-25 yrs; 4/14 sJIA)-13/14 remission, w rapid drops in CXCL9, Ferritin, ALT, DDimers & GC dose #ACR21 ABst LB20 https://t.co/05oW5C8Waf https://t.co/ecEkt3MY83
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) took the centre stage when it was first introduced at ACR20 last year. It got everyone’s thinking that they might have encountered one or two patients in their rheumatology lifetime who might have this condition. One year on, more cases have been reported and this article summarises some breakthroughs pertaining to research in VEXAS.
Traditionally telemedicine is thought to be a technology where a patient directly talks to a provider or a specialist; however, another concept of having a patient with a local primary care who in turn accesses specialists via video conferencing, is gaining some momentum.
Janet Pope Janetbirdope
3 years 7 months ago
The plague protection genetically can lead to Pyrin induced inflammasome activation. Theory of more FMF in Mediterranean / Turkey. So high protection gene in population Dan Kastner - a genetic detective 9T119 #ACR21 #ACRBest @RheumNow https://t.co/qzdc12fT0j
Janet Pope Janetbirdope
3 years 7 months ago
Genes for oral aphthous ulcers common in gen pop’n, Behcets and w auto inflammatory PFAPA - kids w fevers ⬆️IL12 Kastner practical gene stories @RheumNow #ACR21 9T119. Have a listen. Bench to bedside & back https://t.co/UkPzoYbBNb
Poster Hall